Sildenafil Disrupts Cholesterol Transport to Halt Cancer Metastasis in New Study

3 min read
Source: StudyFinds
Sildenafil Disrupts Cholesterol Transport to Halt Cancer Metastasis in New Study
Photo: StudyFinds
TL;DR

A study in Cancer Research suggests sildenafil, the active ingredient in Viagra, may prevent cancer spread by trapping cholesterol inside cancer cells. Mouse models showed reduced metastasis in breast, lung, and colon cancers, while health records of 40,000 men linked combined sildenafil and statin use to a 31% lower five-year mortality risk. Researchers emphasize these are observational findings requiring clinical trials.

Key points

  • Sildenafil blocks the PDE5a enzyme, increasing cGMP levels that jam cholesterol transport proteins (NPC1), trapping cholesterol in cellular recycling compartments (lysosomes).
  • Deprived of usable cholesterol, cancer cells weaken their membranes and mitochondria, reducing their ability to migrate and invade new tissues.
  • In female mice with breast, lung, and colon cancer models, sildenafil significantly reduced lung metastases without necessarily shrinking the primary tumor size.
  • An analysis of Clalit Health Services records in Israel found that men taking both sildenafil and statins had a 31% lower risk of death within five years compared to non-users.
  • The combination of sildenafil and statins (like lovastatin) was more effective in lab tests than either drug alone, as it blocks both cholesterol production and recycling.

Background

This story follows earlier coverage in July and August 2026 regarding the same Weizmann Institute study. Previous reports highlighted the potential of sildenafil to starve tumors of cholesterol, but this briefing synthesizes the full scope of the findings, including the specific mechanism involving NPC1 and the large-scale observational data from Israel. It also connects to broader discussions on how metabolic states and existing medications influence cancer progression.

How outlets are covering it

StudyFinds and Fox News both emphasize the observational nature of the human data, noting that the 31% survival benefit is an association, not proof of causation. Fox News highlights the involvement of the U.S. National Cancer Institute and the potential for combining Viagra with statins. Deccan Herald adds a unique perspective, suggesting sildenafil may also disable myeloid-derived suppressor cells (MDSCs), thereby enhancing the immune system's ability to destroy circulating tumor cells, a detail not prominent in the other sources. All outlets agree that clinical trials are necessary before any medical application.

Why it matters

If confirmed in clinical trials, sildenafil could become a low-cost, widely available adjunct therapy to reduce cancer metastasis. Its decades-long safety profile makes it an attractive candidate for repurposing, potentially improving survival rates for patients already taking statins or other PDE5 inhibitors for unrelated conditions.

What to watch

Researchers plan to conduct clinical trials to test the efficacy and safety of sildenafil and statin combinations in human cancer patients. Further studies are needed to determine optimal dosages, long-term effects, and whether the benefits apply to both male and female patients, as the current animal models were conducted in female mice.

Share this article

Want the full story? Read the original reporting

Read on StudyFinds